Jefferies Financial Group Inc. Takes Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Jefferies Financial Group Inc. acquired a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 192,774 shares of the biopharmaceutical company's stock, valued at approximately $2,462,000. Jefferies Financial Group Inc. owned approximately 0.15% of Dynavax Technologies at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. lifted its holdings in shares of Dynavax Technologies by 4.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock valued at $225,000 after purchasing an additional 771 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Dynavax Technologies by 7.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 904 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 1,076 shares during the last quarter. Sanctuary Advisors LLC increased its position in Dynavax Technologies by 6.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after purchasing an additional 1,109 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,169 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.

Dynavax Technologies Price Performance

Shares of DVAX stock traded up $0.16 during midday trading on Friday, reaching $9.67. 1,573,605 shares of the company were exchanged, compared to its average volume of 2,221,120. Dynavax Technologies Co. has a 12 month low of $9.22 and a 12 month high of $14.63. The company has a market cap of $1.16 billion, a P/E ratio of 53.72 and a beta of 1.26. The company's 50 day moving average price is $11.87 and its two-hundred day moving average price is $12.52. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. On average, sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group reduced their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. StockNews.com downgraded shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, JMP Securities cut their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Dynavax Technologies currently has an average rating of "Hold" and an average target price of $24.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.